| Submission declined on 27 April 2024 by ToadetteEdit (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 19 July 2023 by Tutwakhamoe (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. | |
| Submission declined on 7 March 2023 by Tails Wx (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. | |
| Submission declined on 10 November 2022 by 97198 (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. | |
Comment: Many of the sources did not mentioned the subject at all, and those that did are either published by his institutions, lacks significant coverage, or primarily based on his own publications for sources. Multiple significant coverage are required to show that the subject passes WP:NBIO. Tutwakhamoe (talk) 00:11, 19 July 2023 (UTC)
- Comment: All cited sources are either written by the subject or have a close connection with the subject. 97198 (talk) 01:30, 10 November 2022 (UTC)
Stanley T Crooke | |
|---|---|
| Born | March 28, 1945 |
| Education | MD - Baylor College of Medicine, Houston, TX, 1974
PhD Pharmacology - Baylor College of Medicine, Houston, TX, 1971 BS Pharmacy - Butler University, Indianapolis, IN, 1966 |
Stanley T. Crooke is the founding CEO of Ionis Pharmaceuticals, an RNA-targeted therapeutics company.[1] In 1989, he opened Ionis with the goal of inventing a new drug discovery platform. Over the years, Ionis has developed several drugs including Spinraza, which is designed to treat spinal muscular atrophy (SMA).[2] In 2020, Stan founded the N-Lorem foundation, a non-profit designed to take advantage of the technology discovered at Ionis to provide experimental treatment to patients with extremely rare genetic disorders.[3]
Early Life and Education edit
Stanley Crooke grew up in southwest Indianapolis.[4] Coming from a working-class family, Crooke was the first in his family to finish high school. He studied pharmacy at Butler University, and attempted law school for one week before dropping out. Crooke then attended the Baylor College of Medicine, where he completed a combined MD-PhD program in pharmacology.[4]
Career edit
After working at Bristol Laboratories, Crooke began working in Research and Development at GlaxoSmithKline. Crooke opened Ionis Pharmaceuticals in 1989 under the name Isis Pharmaceuticals, and served as it's CEO until 2019.[5] During this time Several antisense-oligonucleotide therapeutics were registered. Vitravene is used in the treatment of patients with cytomegalovirus retinitis (CMV).[6] Volanesorsen is used in the treatment of patients with familial chylomicronemia syndrome (FCS).[7] Kynamro is used as an orphan drug for the management of homozygous familial hypercholesterolemia (HoFH).[8] Tegsedi is used in the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR).[9]
Dr. Crooke has also worked as an adjunct professor in the Departments of Pharmacology at the University of Pennsylvania, the Baylor College of Medicine and UCSD, the Department of Anatomy and Cell Biology at UCLA, the Department of Biology at San Diego State University.[10]
In 2020, Dr. Crooke founded the n-Lorem Foundation, a non-profit organization that focuses on creating individual experimental treatments for patients with rare genetic diseases. As a non-profit, they provide experimental antisense oligonucleotides to patients for free.[11] Here, he developed an ASO to be the first medication to treat a mutation in the KIF1A gene.[12] He was recognized by the SD500 in 2023 as one of the most influential people in San Diego.[13]
| Year | Award |
|---|---|
| 2022 | Prix Galein Roy Vagellos Pro Bono Humanum Award, New York, NY[14] |
| 2020 | Steven C Beering Award[15] |
References edit
- ^ "Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences". Ionis Pharmaceuticals.
- ^ "Spinraza Treatment for Spinal Muscular Atrophy (SMA) Patients". Columbia Neurology. 2020-11-11. Retrieved 2023-01-18.
- ^ "Leadership". n-Lorem FOUNDATION. Retrieved 2023-01-18.
- ^ a b "The Personal Journey of Stanley Crooke, the Creation and Development of Ionis, and Beyond". Oligonucleotide Therapeutics Society. 2022-09-08. Retrieved 2023-01-18.
- ^ "Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation". Ionis Pharmaceuticals.
- ^ "Fomivirsen - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 2023-01-18.
- ^ Kolovou, Genovefa; Kolovou, Vana; Katsiki, Niki (2022-02-13). "Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia". Journal of Clinical Medicine. 11 (4): 982. doi:10.3390/jcm11040982. ISSN 2077-0383. PMC 8880470. PMID 35207255.
- ^ Wong, Elaine; Goldberg, Tamara (February 2014). "Mipomersen (Kynamro)". Pharmacy and Therapeutics. 39 (2): 119–122. ISSN 1052-1372. PMC 3956393. PMID 24669178.
- ^ Gales, Luís (2019-05-21). "Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis". Pharmaceuticals. 12 (2): 78. doi:10.3390/ph12020078. ISSN 1424-8247. PMC 6631675. PMID 31117178.
- ^ "Graduates | Pharmacology Graduate Group | Perelman School of Medicine at the University of Pennsylvania". www.med.upenn.edu. Retrieved 2023-01-18.
- ^ "Overview". n-Lorem FOUNDATION. Retrieved 2023-01-18.
- ^ "This lifesaving treatment was designed for one. Could it be the future of medical care?". USA TODAY. Retrieved 2023-12-19.
- ^ Lurie, George (2021-11-29). "SD 500 - The Most Influential People in San Diego". San Diego Business Journal. Retrieved 2023-12-19.
- ^ "Roy Vagelos Pro Bono Humanum Award". www.galienfoundation.org. Retrieved 2023-03-16.
- ^ "Steven C Beering Award | Faculty Affairs and Professional Development | IU School of Medicine". medicine.iu.edu. Retrieved 2023-12-19.